scispace - formally typeset
K

Kathleen R. Cho

Researcher at University of Michigan

Publications -  174
Citations -  23081

Kathleen R. Cho is an academic researcher from University of Michigan. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 72, co-authored 169 publications receiving 21341 citations. Previous affiliations of Kathleen R. Cho include Yale University & University of Florida.

Papers
More filters
Journal ArticleDOI

Identification of a chromosome 18q gene that is altered in colorectal cancers

TL;DR: A contiguous stretch of DNA comprising 370 kilobase pairs has now been cloned from a region of chromosome 18q suspected to reside near the DCC gene, which may play a role in the pathogenesis of human colorectal neoplasia, perhaps through alteration of the normal cell-cell interactions controlling growth.
Journal ArticleDOI

p53-Mediated Activation of miRNA34 Candidate Tumor-Suppressor Genes

TL;DR: The data suggest the miRNA34s might be key effectors of p53 tumor-suppressor function, and their inactivation might contribute to certain cancers.
Journal ArticleDOI

Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy.

TL;DR: Using human ovarian cancers as their model, this paper showed that enhancer of zeste homologue 2 (EZH2)-mediated histone H3 lysine 27 trimethylation (H3K27me3) and DNA methyltransferase 1 (DNMT1)-mediated DNA methylation repress the tumour production of T helper 1 (TH1)-type chemokines CXCL9 and CXCl10, and subsequently determine effector T-cell trafficking to the tumours microenvironment.
Journal Article

Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies.

TL;DR: The results support PTEN as a tumor suppressor gene and suggest that mutations in PTEN play a significant role in the pathogenesis of the endometrioid type of endometrial carcinoma.
Journal Article

DPC4 Gene in Various Tumor Types

TL;DR: The results indicate that whereas DPC4 inactivation is prevalent in pancreatic carcinoma (48%), it is distinctly uncommon in the other tumor types examined.